Results 111 to 120 of about 91,153 (299)

Consumer perspectives of accessing medicinal cannabis treatment from cannabis clinics versus generalist health settings in Australia

Journal of Cannabis Research
Objectives To examine consumer perspectives regarding medicinal cannabis treatment provided to patients attending generalist health settings (GHS) compared to those attending medicinal cannabis clinics (MCC).
Nicholas Lintzeris, Jonathon C Arnold, Iain S McGregor, Llewellyn Mills   +3 more
doaj   +1 more source

Suicide attempt and paranoia persisting for 28 days following heavy delta-9-tetrahydrocannabinolic acid and tetrahydrocannabinol use: A case report. [PDF]

PCN Rep
Abstract Background Cannabis contains various cannabinoids, with Δ9‐tetrahydrocannabinol (Δ9‐THC) being the primary psychoactive compound. A non‐psychoactive precursor called Δ9‐tetrahydrocannabinolic acid (THC‐A) is converted to Δ9‐THC slowly over time or rapidly when heated. Cannabis use is linked to psychotic outcomes, with increased risk associated
Greer D, Dey P, Kulig CE.
europepmc   +2 more sources

Synthetic cannabinoids [PDF]

Canadian Medical Association Journal, 2013
Tony, Antoniou, David N, Juurlink
openaire   +2 more sources

Synthetic peripherally-restricted cannabinoid suppresses chemotherapy-induced peripheral neuropathy pain symptoms by CB1 receptor activation. [PDF]

, 2018
Chemotherapy-induced peripheral neuropathy (CIPN) is a severe and dose-limiting side effect of cancer treatment that affects millions of cancer survivors throughout the world and current treatment options are extremely limited by their side effects ...
Mackie, Ken, Marty, Vincent N, Mulpuri, Yatendra, Munier, Joseph J, Schmidt, Brian L, Seltzman, Herbert H, Spigelman, Igor   +6 more
core   +1 more source

Trends in toxicological findings and drug seizures of MDMA in New Zealand from 2010 to 2022

Journal of Forensic Sciences, EarlyView.
Abstract 3,4‐Methylenedioxymethamphetamine (MDMA) or “ecstasy,” is a commonly used drug worldwide, including in New Zealand, where 4.8% of the population aged 15 years or over reported using it in a 2023/2024 survey. This study provides additional insights on MDMA prevalence data in New Zealand by reporting toxicology data from Coronial and driving ...
Thomas J. Sheehan, Hilary J. Hamnett, Sarah G. G. Russell, Diana Kappatos, Helen Poulsen   +4 more
wiley   +1 more source

Derived cannabinoid product availability among online vape shops

Preventive Medicine Reports
Objectives: To determine the proportion of online vape shops that offer derived cannabinoid products in a large metropolitan area (San Diego, California), measure their compliance with state hemp regulations, and estimate whether these shops receive more
Nora Satybaldiyeva, Raquel Harati, Tomas Mejorado, Nicolas Morales, Gustavo Benitez, Shannon E. Ellis, Karen Ferran, Eric C. Leas   +7 more
doaj   +1 more source

Impact of cannabis, cannabinoids and endocannabinoids in the lungs

Frontiers in Pharmacology, 2016
Since the identification of cannabinoid receptors in the 1990s, a research field has been dedicated to exploring the role of the cannabinoid system in immunity and the inflammatory response in human tissues and animal models.
Caroline Turcotte, Marie-Renée Blanchet, Michel Laviolette, Nicolas Flamand   +3 more
doaj   +1 more source

Educating Patients on Cannabidiol (CBD) [PDF]

, 2019
As the popularity of cannabidiol (CBD) increases, more patients are interested in trying a natural adjunct to more standard medications. But with no current FDA oversight, an estimated 70% of CBD products could be mislabeled.
Pratt, Catherine G
core   +1 more source

Pharmacological and Mechanistic Interventions for Cognitive Impairment Associated With Schizophrenia: A Review of Registered Clinical Trials

Acta Psychiatrica Scandinavica, EarlyView.
ABSTRACT Background Schizophrenia is characterized by positive, negative, and cognitive symptoms. Current pharmacological treatments often fail to address cognitive deficits. In this review of clinical trials, we aim to identify studies that explore neurobiological (non‐psychological) strategies to address Cognitive Impairment Associated with ...
Bahareh Peyrovian, Lena Palaniyappan, Theodore T. Kolivakis, Howard C. Margolese   +3 more
wiley   +1 more source

3D-QSAR/CoMFA-Based Structure-Affinity/Selectivity Relationships of Aminoalkylindoles in the Cannabinoid CB1 and CB2 Receptors

Molecules, 2014
A 3D-QSAR (CoMFA) study was performed in an extensive series of aminoalkylindoles derivatives with affinity for the cannabinoid receptors CB1 and CB2.
Jaime Mella-Raipán, Santiago Hernández-Pino, César Morales-Verdejo, David Pessoa-Mahana   +3 more
doaj   +1 more source